Antiviral Drug Development: Overcoming Challenges to the Current Model
Update: 2024-10-11
Description
As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed.
In this podcast, Anil Diwan, President and Executive Chairman of NanoViricides Incorporated, explains some of the shortcomings of the current model of antiviral drug development and how NanoViricides developed a nanotechnology with a different approach to develop and deliver antiviral drugs. Anil also presents an overview of the scientific and clinical development of NanoViricides lead program, NV-387 as well as potential applications in different indications.
For more information about NanoViricides Incorporated, visit NanoViricides.com.
For more information about the annual PODD drug delivery conference, please visit Drug-Delivery.org.
In this podcast, Anil Diwan, President and Executive Chairman of NanoViricides Incorporated, explains some of the shortcomings of the current model of antiviral drug development and how NanoViricides developed a nanotechnology with a different approach to develop and deliver antiviral drugs. Anil also presents an overview of the scientific and clinical development of NanoViricides lead program, NV-387 as well as potential applications in different indications.
For more information about NanoViricides Incorporated, visit NanoViricides.com.
For more information about the annual PODD drug delivery conference, please visit Drug-Delivery.org.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
